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The study by Gowda et al. (1) in this issue of the Journal
challenges the “legitimacy” of angiography as the gold
standard for the diagnosis of renal artery stenosis due to
fibromuscular dysplasia (FMD). It reinforces the dilemma
caused by the limited evidence-based approach to the
diagnosis and treatment of renal artery stenosis regardless of
etiology. Though there is a general consensus that percuta-
neous transluminal angioplasty is the procedure of choice
for FMD and is both safe and effective, the evidence for this
is dated, largely descriptive, and reported in the prestent era.
For the much more common setting of atherosclerotic renal
artery stenosis, a few widely quoted randomized compara-
tive trials with serious flaws in study design, execution, and
interpretation have led to the conventional wisdom by many
that renal revascularization is ineffective (an opinion we do
not share). When compared to other areas of endovascular
intervention, the evidence base in this field is quite inferior.
See page 1305
For the present, the decision to pursue percutaneous
therapy is based on descriptive single-center series, multi-
center registries, and some largely anecdotal reports suggest-
ing that percutaneous revascularization decreases the need
for antihypertensive medication, cures hypertension in a
small minority, and slows the progression to renal failure in
atherosclerotic renal artery disease (2–4). The superiority of
endovascular therapy over medical therapy has not been
shown (5–7). The evidence for intervention in FMD is
somewhat more compelling (8–11), but the incidence of
fibromuscular disease is quite low, likely only 1/10th as
common as atherosclerotic renal artery stenosis. Fibromus-
cular dysplasia of the renal arteries accounts for 1% of the
hypertensive population; therefore, it is an uncommon
clinical scenario in clinical practice (12).
Algorithms for screening for renal artery stenosis are also
debated, with a wide range of techniques available including
duplex ultrasonography, contrast-enhanced magnetic reso-
nance arteriography (MRA), three-dimensional computed
tomography (CT), and selective or nonselective contrast
angiography (13). Because of lower accuracy, nuclear renal-
flow scanning and plasma renin assays, both with or without
angiotensin-converting enzyme inhibitor stimulation, are
less commonly employed (14). Angiography has remained
the gold standard in most studies.
EVIDENCE BASE TO DATE
Only a few randomized trials to date have examined the
efficacy of percutaneous revascularization compared with
medical therapy or surgery, each with significant design,
enrollment, or data analysis problems (Table 1). Four such
studies have been reported in the literature (5–7,15), three
in comparison with medical therapy and one with surgical
revascularization. A recent meta-analysis of the three med-
ical therapy versus balloon angioplasty studies (5–7) found
only a small, although significant reduction in blood pres-
sure in patients undergoing intervention (16). These studies
have at least some faults in common: stents were rarely used
although they have become the de facto standard for
percutaneous endovascular intervention in atherosclerotic
renal artery stenosis (3); some or all of the interventionists
lacked experience; the studies were underpowered; substan-
tial crossover occurred; and there were significant design
and enrollment problems.
Particular criticism has been leveled at the largest of these
studies, from the Dutch Renal Artery Stenosis Interven-
tion Cooperative Study Group (5), which concluded that
“In the treatment of patients with hypertension and renal-
artery stenosis, angioplasty has little advantage over
antihypertensive-drug therapy.” This widely quoted study
had several egregious issues. One hundred six patients were
enrolled at 26 sites, thus averaging only two angioplasty
patients per site over a six-year period. The investigators’
results do not demonstrate efficacy of endovascular therapy
as reported by researchers with extensive experience and
expertise. Several other factors may have contributed to a
Type II error: nearly half the medical therapy cohort
underwent angioplasty after the first three months because
of failure to control blood pressure on medication or
decreased renal function; a significant percentage of the
patients had less than critical stenosis (10% had 50%
stenosis, an unspecified number had 60%); and the end
point was one year, a time frame at which many patients
undergoing balloon angioplasty would have sustained reste-
nosis (the three-month results were more favorable). Stent-
ing likely would have had substantially better results.
Although there is extensive nonrandomized evidence that
stenting is superior to balloon angioplasty (17), only one
published study has compared balloon angioplasty with
stenting (18), although the latter has become the standard of
care. In that study, restenosis was 48% with balloon angio-
plasty versus 14% with stenting at six months; acute success
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was only 57% with balloon angioplasty versus 88% with
stenting. In comparing medical therapy and stenting, the
clinician is left without randomized clinical data. There
remain conservative physicians who suggest that stenting
should be reserved as a bail-out procedure, but it is our
opinion that this approach is difficult to justify (19).
STUDY DESIGN AND PATIENT ENROLLMENT
The premise of the study by Gowda et al. (1), along with
their methods and conclusions, raises potential concerns. A
small number of patients with abnormal color flow duplex
imaging (CFDI) underwent intravascular ultrasound
(IVUS) and renal angiography. It is unclear how many
patients were screened during the 28-month period, how
many had abnormal renal artery duplex ultrasound exami-
nations that were not suggestive of FMD, or how the
criteria for noninvasive diagnosis of FMD utilizing duplex
ultrasonography were derived. The mean age of 62 years
(including an 86-year-old) is rather remarkable for a disease
primarily occurring in young women (20). Whereas various
criteria have been proposed for invasive screening (21), it is
unclear whether these patients met the criteria.
Noninvasive assessment. The investigators (1) claim that
100% of screened patients had successful completion of
diagnostic studies despite performing ultrasound in the
supine position only. The vast majority of renal arteries
(particularly the mid and distal vessels) cannot be fully
imaged with the patient supine (22), thus requiring placing
the patient in the lateral decubitus position. The technique
of duplex ultrasonography of the renal arteries is “time-
consuming, technically demanding and has a steep learning
curve” (23). We continue to experience an approximately
10% failure rate for a complete examination of both renal
arteries (full visualization from the ostium to the hilum of
the kidney). This is in keeping with the residual failure rate
of duplex ultrasonography of up to 20% reported in labo-
ratories with highly experienced personnel (24,25). Al-
though Gowda et al. (1) claim that improved techniques
mitigate the presence of bowel gas and obesity, those factors
as well as difficulties inherent in imaging small vessels, the
posterior location of the mid and distal arteries, inability of
patients to hold their breath, and simply being unable to
obtain a good acoustic window remain unresolved problems.
Use of ultrasound contrast and improved technology will
likely reduce the failure rate in the future.
Gowda et al. (1) have introduced criteria for ultrasound
detection of FMD including a renal:aortic systolic flow
velocity ratio 2.0 and “abnormal, non-laminar flow pat-
terns (such as aliasing and spiraling flow)” that do not have
the weight of known methodology or published literature.
The flow velocity ratio used by the investigators is at
variance with the accepted standard of 3.5. A ratio of
2.0 has limited specificity and would have included the
majority of patients without significant stenosis in prior
studies (23). In fact, only 10 of the 32 renal arteries said to
have FMD demonstrated higher systolic velocity ratios, and
we do not know what the correlation of these vessels was
with angiography. The flow pattern description is also
unfamiliar, and we are not aware of any such criteria in the
published reports. “Aliasing” is not related to laminar flow,
but rather to the pulse repetition frequency of a particular
Doppler waveform, whereas “spiraling” is a low-specificity
descriptive feature and not a term commonly associated with
duplex imaging. It is not clear whether all these criteria were
prospectively evaluated and validated.
As with the definition of duplex criteria for FMD, the
definition of IVUS findings consistent with this disease
appears ad hoc; we are unaware of established criteria with
appropriate correlation with pathological findings. Because
the IVUS findings are being used as confirmatory of the
CFDI observations, this further raises questions regarding
the interpretation of the investigators’ data. At the same
time, Gowda et al. (1) state that “in some patients whose
contralateral renal arteries were normal or borderline and
whose CFDI was normal, IVUS was performed and was
uniformly normal.” Not having been told how many pa-
tients or arteries this represented, it is hard to know how
much emphasis to place on “uniformity” or even how to
interpret this finding.
Angiographic evaluation. The angiographic evaluation of
these patients may have been marred by a number of factors.
First, the three cardiologists reviewed the angiograms for
“the classic beaded appearance” of FMD, although this is
seen in only approximately 75% of cases (12); there are five
distinct types of FMD, and failure to screen for the others
may have resulted in false negatives. The choice of a
“10–20° right anterior oblique projection for the right renal
artery . . . to view the ostium clearly” was not ideal in that
it maximizes foreshortening and actually minimizes the
odds of complete visualization, given that the artery courses
30° ventrally from its origin at the aorta (26). In addition,
the ostium is not the area of primary interest for FMD,
Table 1. Randomized Trials in Renal Artery Stenosis Intervention
Year n Medical Balloon Stent Surgery End Points
Weibull (15) 1993 58 X X BP/renal function
Plouin (7) 1998 49 X X BP
Webster (6)* 1998 55 X X BP/renal function
van de Ven (17) 1999 84 X X Patency/BP/renal function
van Jaarsveld (5) 2000 106 X X BP/renal function
*Five patients underwent nephrectomy or bypass surgery in lieu of angioplasty.
BP  blood pressure.
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although it is for atherosclerosis (27). Second, the investi-
gators state that it “should not be surprising” that there was
failure to detect by angiography the “very short, planar,
cleft-like lesions [that] can escape detection in all but one
optimal view.” This may well have been due to their view
selection. Third, by using selective angiography, the inves-
tigators likely missed accessory renal arteries (estimated to
occur in about 20% of patients (28) that may originate
anywhere from the lateral aorta to the iliac arteries, that may
arise at steep angulations up to 90° from their origin, may be
difficult to interrogate using appropriate Doppler angles,
may be quite small, occur in groups of three or more, and be
difficult to detect by ultrasound.
The study by Leung et al. (25), which enrolled hyperten-
sive patients and obtained duplex, MRA, and angiography
of 85 renal arteries, using angiography as the gold standard
is of questionable applicability, given that only 5 of the 45
abnormal arteries had FMD. It should be noted that duplex
ultrasonography resulted in seven false positive and seven
false negative readings. With regard to the conclusion by
Beregi et al. (29) suggesting that renal angiography with
pressure measurements should be the gold standard, it is our
observation in FMD (unlike with atherosclerotic disease)
that translesional pressure measurements are unreliable
markers of severity of obstruction. There is no published
evidence that “hydraulic assessment is a better predictor
(than percent stenosis by arteriography) of response to
revascularization” in FMD.
Based on the small number of patients, the problems
inherent in the screening process, and the technique issues
raised by the methodologies used with each of the measure-
ment end points, we do not believe that a compelling case
can be made for abandoning renal angiography as the gold
standard. We also cannot recommend abandoning arterio-
graphic criteria and using balloon angioplasty in angio-
graphically normal-appearing arteries based on the data
presented. Furthermore, we would be very cautious about
accepting the diagnosis of fibromuscular dysplasia and
oversizing noncompliant balloons in the renal arteries of
elderly patients as described by Gowda et al. (1). We
maintain that the appropriate algorithm for the diagnosis of
fibromuscular dysplasia of the renal arteries remains a high
clinical index of suspicion, a potentially abnormal renal
artery duplex ultrasound, CT angiogram or MRA study,
and a confirmatory contrast arteriogram.
THE FUTURE
Various unpublished initiatives are under way to provide an
evidence base. The ASPIRE trials (Action on Secondary
Prevention through Intervention to Reduce Events) en-
rolled patients who underwent stenting after suboptimal
balloon angioplasty; this was a nonrandomized safety and
efficacy study. Preliminary data on 208 patients presented at
the 2002 American Heart Association Scientific Sessions
revealed a 16.8% nine-month restenosis rate (30). A trial in
the planning stage, CORAL (Cardiovascular Outcome in
Renal Atherosclerotic Lesions), is designed to compare
medical therapy versus medical therapy plus stenting.
RESIST (Randomized Comparison of Safety and Efficacy
of Renal Stenting) is an ongoing trial comparing renal
stenting with or without distal protection and with or
without glycoprotein IIb/IIIa inhibition to assess renal
function. The design problems facing these studies are
substantial, including the need for a sensitive end point to
assess the affect of intervention on the kidney. In an attempt
to provide a level playing field with well-designed enroll-
ment criteria, study populations, and outcomes reporting, a
consortium of American Heart Association councils and the
Society of Interventional Radiology FDA Device Forum
Committee have published guidelines for future trials (31).
Until there is clarity provided by these trials, the clinician
will be forced to continue practice based upon existing
standards, waiting for evidence to support the therapeutic
alternatives.
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